Novartis responds to ASRS update on safety of Beovu

February 25, 2020
Representatives from Novartis stood behind the safety and efficacy of Beovu, a treatment for wet age-related macular degeneration, after the American…

ReNeuron stem cell therapy shows positive long-term results in retinitis pigmentosa

February 25, 2020
ReNeuron’s hRPC stem cell therapy candidate has shown a meaningful clinical effect in patients with retinitis pigmentosa at 12 months…

Meeting News

Fundus photography may help differentiate TIA, stroke from mimic

February 24, 2020
Nonmydriatic fundus photography after suspected minor stroke or transient ischemic attack was able to differentiate between actual stroke and mimics…

Meeting NewsVideo

VIDEO: The e-health revolution in health care

February 21, 2020
TREVISO, Italy — At the Retina 2020: New Trends meeting, Claudio Azzolini, MD, speaks about e-health and the many opportunities it provides…

Enrollment complete in two more cohorts in X-linked retinitis pigmentosa gene therapy trial

February 21, 2020
Enrollment is complete in the two highest dose groups in a phase 1/2 clinical trial evaluating an adeno-associated virus-based gene therapy for the…


SURGICAL VIDEO: Persistent hyperplastic primary vitreous

February 20, 2020
This video showcases the steps involved in the surgical management of a case of persistent hyperplastic primary vitreous, or PHPV. After conjunctival…

LumiThera expands Valeda research into diabetic retinopathy

February 20, 2020
LumiThera is expanding research of its photobiomodulation platform, the Valeda light delivery system, with new studies evaluating its use in patients…

Meeting News

OCS-01 shows clinical proof of concept in DME treatment

February 20, 2020
Phase 2 data for OCS-01, a proprietary topical nanoparticle formulation of dexamethasone from Oculis to treat patients with diabetic macular edema…

Meeting News

Latest data on ADVM-022 in OPTIC phase 1 trial released

February 19, 2020
Four of six patients with neovascular age-related macular degeneration treated with a threefold lower dose of ADVM-022 in the OPTIC phase 1 trial did…

Beovu approved for wet AMD in Europe

February 17, 2020
The European Commission has approved Beovu for the treatment of wet age-related macular degeneration, Novartis announced in a press release. Beovu…

Meeting News

Phase 1 study of THR-687 for DME shows improvement in vision

February 13, 2020
An open-label, multicenter, single dose escalation study evaluating the safety of a single intravitreal injection of three increasing doses of…

Grand Rounds at the New England Eye Center

Young woman presents with unilateral eye discomfort

Ocular Surgery News U.S. Edition, February 25, 2020
Christine L. Benador-Shen, MD; Geetha Athappilly, MD; Thomas R. Hedges III, MD
A 24-year-old African American woman with a medical history of right-sided Bell’s palsy, hidradenitis suppurativa and borderline hypertension…


What circumstances would make brolucizumab your anti-VEGF drug of choice?

Ocular Surgery News U.S. Edition, February 25, 2020
Exudative age-related macular degeneration is the leading cause of blindness in the developed world in people older than 65 years of age. Numerous…

Cover Story

Successful retinal injection practice depends on clinical efficiency, patient satisfaction

Ocular Surgery News U.S. Edition, February 25, 2020
Anti-VEGF injections can help maintain and sometimes improve visual acuity in patients with degenerative retinal diseases, but there is an associated…

Grading of DR by first-line caregivers needs improvement

Ocular Surgery News U.S. Edition, February 25, 2020
The majority of optometrists perform a dilated fundus examination to screen for diabetic retinopathy, but the concordance between the examination and…

Lindstrom's Perspective

Advances needed to alleviate burden of retinal disease treatment

Ocular Surgery News U.S. Edition, February 25, 2020
Richard L. Lindstrom, MD
We now have our fourth anti-VEGF drug, Beovu from Novartis. Each of the available drugs — Avastin, Lucentis, Eylea and Beovu — typically…

Meeting News

Eylea reduced risk for vision-threatening complications at 2 years

February 12, 2020
The 2-year results of the phase 3 PANORAMA trial evaluating intervention with aflibercept for patients with moderately severe to severe…

Meeting News

Diabetic retinopathy confers stroke risk in diabetes

February 12, 2020
Among patients with diabetes, those with diabetic retinopathy had elevated stroke risk compared with those who did not, according to new data from…


BLOG: Angiogenesis 2020: Noteworthy and notable presentations

February 11, 2020
The Bascom Palmer Angiogenesis meeting took place on Feb. 8, covering disease pathogenesis and emerging treatment options for various retinal…

Positive results seen in fourth cohort of OpRegen phase 1/2a study

February 10, 2020
Based on positive early data available for the first five patients in a phase 1/2a clinical study of OpRegen, Lineage Cell Therapeutics announced it…